Economic evaluation of interventions in endocrinology

Endocrinology and Metabolism Clinics of North America

Volumn 26, Issue 1, 1997, Pages 67-87

  Taylor, T N ^a   Chrischilies, E A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENDOCRINOLOGY; HEALTH CARE COST; HUMAN; LASER COAGULATION; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0031003505     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70234-6     Document Type: Article

References (52)

1. American Diabetes Association Direct and Indirect Costs of Diabetes in the United States in 1992 1993 American Diabetes Association Alexandria, VA
2. Australian Commonwealth Department of Human Services and Health Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee Including Major Submissions Involving Economic Analyses 1995 Australian Government Publishing Service Canberra
3. E. Barrett-Connor The economic and human costs of osteoporotic fracture Am J Med 28 suppl 2A 1995 3S
4. K. Borch-Johnsen H. Wenzell G.C. Viberti Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes? BMJ 306 1993 1722
5. A.P. Cheung B.G. Wren A cost-effectiveness analysis of hormone replacement therapy in the menopause Med J Aust 156 1992 312
6. E. Chrischilies T. Shireman R. Wallace Costs and health effects of osteoporotic fractures Bone 15 1994 377
7. D.J. Cook G.H. Guyatt J.D. Adachi Quality of life issues in women with vertebral fractures due to osteoporosis Arthritis Rheum 36 1993 750
8. E. Daley M. Roche D. Barlow HRT: An analysis of benefits, risks, and costs Br Med Bull 48 1992 368
9. E.J. Dasbach D.G. Fryback P.A. Newcomb Cost-effectiveness of strategies for detecting diabetic retinopathy Med Care 29 1991 20
10. DCCT Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977
11. DCCT Research Group Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial JAMA 276 1996 1409
12. M.F. Drummond G.L. Stoddart G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes 1987 Oxford University, Press New York
13. M. Drummond G. Torrance J. Mason Cost-effectiveness league tables: More harm than good? Soc Sci Med 37 1993 33
14. J.A. Eisman Efficacy of treatment of osteoporotic fractures Am J Med 98 suppl ZA 1995 17S
15. S.A. Finkler The distinction between costs and charges Ann Intern Med 96 1982 102
16. R.M. Francis F.H. Anderson D.J. Torgerson A comparison of the effectiveness and cost of treatment for vertebral fractures in women Br J Rheumatol 34 1995 1167
17. P. Gardsell O. Johnell B.E. Nilsson Predicting fractures in women by using forearm bone densitometry Calcif Tissue Int 44 1989 235
18. M.R. Gold L.B. Russell J.E. Siegel Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
19. M.R. Gold D.L. Patrick G.W. Torrance Identifying and valuing outcomes M.R. Gold J.E. Siegel L.B. Russell Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York 82
20. S. Greenfield S.H. Kaplan R.A. Silliman The uses of outcomes research for medical effectiveness, quality of care, and reimbursement in type II diabetes Diabetes Care 17 suppl 1 1994 32
21. M.-J. Haardt J.-L. Selam G. Slama A cost-benefits comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes Diabetes Care 17 1994 847
22. A.L. Hillman J.M. Eisenberg M.V. Pauly Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies N Engl J Med 324 1991 1362
23. S.L. Hui C.W. Slemenda C.C. Johnston Baseline measurement of bone mass predicts fracture in white women Ann Intern Med 111 1989 235
24. J.C. Javitt J.K. Canner A. Sommer Cost effectiveness of current approaches to the control of retinopathy in type I diabetics Ophthalmology 96 1989 255
25. J.C. Javitt J.K. Canner R.G. Frank Detecting and treating refinopathy in patients with type I diabetes mellitus: A health policy model Ophthalmology, 97 1990 483
26. J.C. Javitt L.P. Aiello L.J. Bassi Detecting and treating retinopathy in patients with type I diabetes mellitus: Savings associated with improved implementation of current guidelines Ophthalmology 98 1991 1565
27. J.C. Javitt L.P. Aiello Y. Chiang Preventive eve care in people with diabetes is cost-saving to the federal government Diabetes Care 17 1994 909
28. J.C. Javitt L.P. Aiello Cost-effectiveness of detecting and treating diabetic retinopathy Ann Intern Med 124 1 pt 2 1996 164
29. M. Johannesson B. Jonsson Economic evaluation in health care: Is there a role for cost-benefit analysis? Health Policy 17 1991 1
30. C.C. Johnston L.J.I. Melton T. Lindsay Clinical indications for bone mass measurements: A report from the Scientific Advisory Board of the National Osteoporosis Foundation J Bone Miner Res 4 suppl 2 1989 1
31. B.A. Kiberd K.K. Jindal Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation BMJ 311 1995 1595
32. N.G. Kutner M.G. Ory D.I. Baker Measuring the quality of life of the elderly in health promotion intervention clinical trials Public Health Rep 107 1992 530
33. D.R. Lairson J.A. Pugh A.S. Kapadia Cost-effectiveness of alternative methods for diabetic retinopathy screening Diabetes Care 15 1992 1369
34. J.R. Lave C.L. Pashos G.F. Anderson Costing medical care: Using Medicare administrative data Med Care 32 1994 JS77
35. R. Lindsay The burden of osteoporosis: Cost Am J Med 98 suppl 2A 1995 9S
36. B.R. Luce A. Elixhauser Standards for the Socioeconomic Evaluation of Health Care Services 1990 Springer-Verlag New York
37. B.R. Luce W.G. Manning J.E. Siegel Estimating costs in cost-effectiveness analysis M.R. Gold J.E. Siegel L.B. Russell Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York 176
38. L.J. Melton D.M. Eddy C.C. Johnston Jr Screening for osteoporosis Ann Intern Med 112 1990 516
39. Omnibus Budget Reconciliation Act of 1987, Public Law 100-203, sect. 4072, 100th Congress, 1st Session, December 27, 1987
40. A. Ravinkar Compliance with hormone therapy Am J Obstet Gynecol 156 1987 1332
41. C. Ribot F. Tremollieres J.-M. Pouilles Can we detect women with low bone mass using clinical risk factors? Am J Med 98 suppl 2A 1995 52
42. D.G. Seeley W.S. Browner M.C. Nevitt Which fractures are associated with low appendicular bone mass in elderly women? The study of osteoporotic fractures research group Arm Intern Med 115 1991 837
43. J.E. Siegel A.S. Krolewski J.H. Warram Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus J Am Soc Nephrol 3 1992 Sl11
44. Task Force on Principles for Economic Analysis of Health Care Technology Economic analysis of health care technology: A report on principles Ann Intern Med 123 1995 60
45. D.J. Torgerson D.M. Reid Osteoporosis prevention through screening: Will it be cost-effective? Bailliere's Clin Rheumatol 7 1993 603
46. G.W. Torrance D. Blaker A. Detsky Canadian guidelines for economic evaluation of pharmaceuticals PharmacoEconomics 9 1996 535
47. A.N.A. Tosteson D.I. Rosenthal L.J. Melton Cost-effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy Ann Intern Med 113 1990 594
48. S. Udvarhelyi G.A. Colditz A. Rai Cost-effectiveness and cost-benefit analyses in the medical literature: Are the methods being used correctly? Ann Intern Med 116 1992 238
49. Congress US, Office of Technology Assessment Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy Cost-effectiveness Analysis. OTA-BP-H-160 vol I August 1995 US Government Printing Office Washington, DC
50. M.C. Weinstein Estrogen use in postmenopausal women— costs, risks, and benefits N Engl J Med 303 1980 308
51. M.C. Weinstein I. Schiff Cost-effectiveness of hormone replacement therapy in the menopause Obst Gynecol Surv 38 1983 445
52. J. Wooldridge L. Moreno Evaluation of the costs to Medicare of covering therapeutic shoes for diabetic patients Diabetes Care 17 1994 541